Let’s talk.
Whether you’re a research group, a data partner, or just curious about the platform, we’d love to hear from you. Reach the right team directly and we’ll get back to you.
Latest news
Modelling Celtic Biotech's CB-24 across 831 oncology cell lines
Meta-Flux is collaborating with fellow Dublin company Celtic Biotech to profile its lead candidate CB-24 across 831 oncology cell lines, modelling sensitivity and resistance to point the therapeutic towards the patients most likely to respond.
Read moreMeta-Flux named Drive Startup of the Year by MassBio
Meta-Flux has been named Drive Startup of the Year at MassBio's 2026 State of Possible Conference in Boston, recognising our mechanistic, in silico approach to disease simulation and early traction with therapeutics partners.
Read moreMeta-Flux and Mercury Bio partner to model CNS drug delivery in silico
Meta-Flux is working with Santa Fe-based Mercury Bio to bring mechanistic, in silico modelling to its brain-delivery therapeutics, sharpening target selection and biomarker strategy in Parkinson's and Alzheimer's before wet-lab and clinical work begins.
Read moreMeta-Flux raises €1.8 million in pre-seed funding
Meta-Flux has raised €1.8 million in pre-seed funding, backed by senior executives from Pfizer, Merck, and Gilead and technology leaders from Google, Amazon, and Indeed, to scale its mechanistic, in silico models of disease.
Read more